Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Drug Manufacturers - Specialty & Generic

Healthcare
$29.71 -1.60%

-$0.31 today

Market cap
$1.27B
Beta
0.90
P/E (TTM)
10.9
EPS (TTM)
$1.75
52W Low $16.65High $31.26

Volume 0.53M

Average 0.59M

AMPH EBITDA Margin

EBITDA as a percentage of revenue.

Amphastar Pharmaceuticals, Inc.NASDAQ: AMPH

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 19.3%

EBITDA Margin was 19.3% in Q1 FY2026, down 11.4 pp from a year earlier. On a trailing-twelve-month basis it was 26.6%, down 9.0 pp year over year. Over 3 fiscal years it widened by 0.2 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 35.1% for the fiscal year ending Dec 2026, up from 29.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
19.3%-10.4 pp QoQ
Last fiscal yearDec 2025
29.5%-8.4 pp YoY
LTMMar 2026
26.6%-9.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-11.4 pp-3.9 pp+7.5 pp
1 year-8.4 pp+5.6 pp+14.0 pp
3 years+0.2 pp+6.6 pp+6.4 pp
5 years+2.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
29.5%
Year-over-year change
-8.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How AMPH compares with its peers on the latest reported figures

  • AMPH's LTM Mar 2026 EBITDA Margin of 26.6% is the 2nd highest of the 8 companies compared; the peer median is 18.4%.
  • Its year-over-year change of -9.0 pp is the 6th highest of 8, against a peer median of +0.5 pp.
  • Over three fiscal years its change of +0.2 pp compares with a peer median of +0.1 pp.
AMPH Competitors Peer median
EBITDA Margin for AMPH and competitors
Company Period LTM level YoY 3-year change
COLLCollegium Pharmaceutical, Inc.LTM Mar 202676.6% +26.5 pp+14.0 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202626.6% -9.0 pp+0.2 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202620.9% +0.5 pp+0.1 pp
BHCBausch Health Companies Inc.LTM Jun 202618.9% -14.3 pp-4.5 pp
VTRSViatris Inc.LTM Jun 202618.4% +21.9 pp-42.3 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202616.3% -12.5 pp-6.7 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202615.0% -2.9 pp+24.4 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 20266.3% +9.1 pp+39.4 pp
Peer median (excluding AMPH) 18.4%+0.5 pp+0.1 pp

Competitors are the stored peer set for AMPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue437.77M498.99M644.4M731.97M719.89M
Cost of Revenue238.03M250.13M293.27M358.11M363.83M
Gross Profit199.74M248.86M351.12M373.86M356.06M
Gross Margin45.6%49.9%54.5%51.1%49.5%
Research & Development60.93M74.77M73.74M73.91M85.84M
Selling, General & Admin68.92M66.59M80.39M94.52M129.81M
Operating Expenses129.85M141.36M154.13M168.44M215.65M
Depreciation & Amortization26.53M28.28M41.78M57.21M63.2M
EBITDA111.56M146.16M240.29M277.31M212.31M
EBITDA Margin25.5%29.3%37.3%37.9%29.5%
Operating Income69.89M107.5M196.99M205.42M140.4M
Operating Margin16.0%21.5%30.6%28.1%19.5%
Interest Income601K1.32M5.46M10.61M8.68M
Interest Expense885K1.85M27.16M30.34M25.48M
Other Income / Expenses14.04M7.37M(27.61M)(16.23M)(16.78M)
Income Before Tax83.93M114.86M169.38M189.19M123.62M
Pre-Tax Margin19.2%23.0%26.3%25.8%17.2%
Income Tax Expense20.63M23.48M31.83M29.67M25.53M
Net Income62.12M91.39M137.55M159.52M98.09M
Net Margin14.2%18.3%21.3%21.8%13.6%
EPS (Basic)1.301.882.853.292.10
EPS (Diluted)1.251.742.603.062.03
Weighted Avg Shares47.78M48.55M48.27M48.43M46.74M
Weighted Avg Shares (Diluted)49.78M52.43M53M52.06M48.22M

Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Intrinsic Alpha fair value

Locked

Current Price

$29.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.